

## **Management of Central Post-Stroke Pain: Systematic Review and Meta-Analysis**

Arnas Tamasauskas<sup>a</sup>, Andrew Marshall<sup>a</sup>, Barbara Silva-Passadouro<sup>b</sup>, Nichollas Fallon<sup>a</sup>,  
Bernhard Frank<sup>a</sup>, Svajune Laurinaviciute<sup>c</sup>, and Simon Keller<sup>a</sup>

Affiliations: <sup>a</sup>University of Liverpool, United Kingdom; <sup>b</sup>University of Leeds, United Kingdom; <sup>c</sup>MTC Group

Number of Text Pages: 16

Number of Figures: 8

Number of Tables: 4

Correspondence: Arnas Tamasauskas, [arnas.tamasauskas@liverpool.ac.uk](mailto:arnas.tamasauskas@liverpool.ac.uk), +447787345883,  
The Pain Relief Foundation, University Hospital Aintree, Clinical Sciences Centre, Liverpool  
L9 7AL; ORCID: 0009-0002-0035-2973.

## Abstract

1 Central post stroke pain (CPSP) is a neuropathic pain condition prevalent in 8% to 35% of  
2 stroke patients. This systematic review and meta-analysis aimed to provide insight in the  
3 effectiveness of available pharmacological, physical, psychological, and neuromodulation  
4 intervention in reducing pain in CPSP patients. Secondary outcomes included mood, sleep,  
5 global impression of change, and physical responses. Data extraction included participant  
6 demographics, stroke aetiology, pain characteristics, pain reduction scores, and secondary  
7 outcome metrics. Forty two original studies were included with a total of 1451 participants.  
8 Twelve studies met requirements for a random-effects meta-analysis which found:  
9 neuromodulation to be the most effective with a moderate effect on pain scores (SMD = -0.60,  
10 95% confidence interval [-0.97, -0.23]), followed by physical interventions with moderate  
11 effect (SMD = -0.55, [-1.28, 0.18]), and pharmacological interventions with a small effect on  
12 pain (SMD = -0.36, [-0.68, -0.03]). Fourteen studies were included in proportional meta-  
13 analysis with pharmacological studies having a moderate effect (58.34% mean reduction,  
14 [36.50, 80.18]), and neuromodulation studies a small effect (31.70% mean reduction, [21.44,  
15 41.96]). Sixteen studies were included in the narrative review. While the overall medium risk  
16 of bias limits generalisation of findings, fluvoxamine and repetitive transcranial magnetic  
17 stimulation was found to have consistently good pain alleviation and relatively low risk of side  
18 effects. Anticonvulsants were found to have a significant effect on pain reduction, but were  
19 found to have the most side effects. Virtual reality and acupuncture show promising results,  
20 but lack rigorous methodological investigation to understand their full effect.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 1 Introduction

1 Central Post Stroke Pain (CPSP) is a neuropathic pain condition evident in 8% to 35% of stroke  
2 patients[48,57]. CPSP is characterised by spontaneous pain and abnormal somatosensory  
3 reaction to sensations, such as: touch, vibration, heat and cold. Pain severity reported by  
4 patients ranges from moderate to severe, but on average CPSP patients reported their pain  
5 intensity as 6 on an 11 point Visual Analogue Scale (VAS)[28,42]. The onset and qualities of  
6 pain can differ between CPSP patients. Spontaneous pain is most common and found in 85%  
7 of patients[44]. This type of pain can be either continuous or Paroxysmal, and is described as  
8 burning, aching, pricking, or shooting. CPSP patients may also experience evoked pain in  
9 conjunction with spontaneous pain or in absence of it. Evoked pain can present as either  
10 hyperalgesia to nociceptive stimuli, or allodynia to non-nociceptive thermal or touch stimuli.  
11  
12  
13

14 Conversely, CPSP may result in negative sensory symptoms with a reduced sensation to tactile  
15 and thermal stimuli. Up to 66% of CPSP patients experience impaired perception of pinprick,  
16 touch, and thermal stimuli[48]. A smaller portion of CPSP patients also experience impairment  
17 of vibration sensation perception. As patients exhibit varied combinations of positive and  
18 negative sensory signs, CPSP can be difficult to diagnose.  
19  
20

21 It has been suggested that a CPSP diagnosis requires the patient to have developed pain after  
22 stroke, have experienced a central nervous system lesion as evidenced by brain imaging, and  
23 exclusion of other neuropathic causes of pain and non-neuropathic post stroke pain[87].  
24 However, the diagnostic criteria vary in practice with some clinicians not requiring exclusion  
25 of other pain conditions, and other clinicians requiring additional criteria, such as including  
26 abnormal sensory testing to temperature[47].  
27  
28  
29

30 The onset of CPSP is also variable with symptoms appearing imminently after stroke or a few  
31 years after stroke[57]. Coupled with variable diagnostic criteria, inconstant onset times result  
32 in treatment delays[28]. Early CPSP research placed great emphasis on Thalamic lesions as a  
33 cause for CPSP and referred to CPSP as ‘Thalamic Syndrome’. However, this was found to be  
34 an oversimplification as not all patients with Thalamic lesions developed CPSP, and,  
35 conversely, not all patients with CPSP had Thalamic lesions[28]. The presence of a lesion in  
36 the spinothalamic pathway does seem to increase the likelihood of developing CPSP but the  
37 exact pathomechanisms of this condition are still being investigated[47].  
38  
39  
40

41 CPSP patients are also at a higher risk of developing physical and psychological comorbidities.  
42 One prevalence study reported the presence of non-CPSP pain in over 57% of CPSP  
43 patients[45]. This included headaches, shoulder pain, and pain due to muscle spasms. Among  
44 psychological comorbidities, CPSP patients experience higher levels of depression, insomnia,  
45 drug dependency, and suicide risk[28,48]. These comorbidities were more prevalent in patients  
46 with CPSP than in stroke patients without CPSP or stroke patients with dysaesthesia[4]. Albeit,  
47 the evidence for this is from relatively small prevalence studies, and the association of CPSP  
48 and comorbidities requires further investigation.  
49  
50  
51

52 Currently, CPSP is regarded as a long-term condition with some speculation that it is life-  
53 long[44]. There are no successful disease modifying treatments, but a number of approaches  
54 have been explored to reduce CPSP symptoms. From a population-based study, antidepressants  
55 were found to be the most common treatment for CPSP as tricyclic antidepressants and  
56 serotonin reuptake inhibitors were found, to an extent, to alleviate pain and associated  
57 psychological comorbidities[24]. Antidepressants followed by paracetamol and opioids were  
58  
59  
60  
61  
62  
63  
64  
65

1 the commonly used pain relief. Antiepileptics were the third most popular pharmacological  
2 treatment with about 25% of participants taking some type of antiepileptic. However, the  
3 effectiveness of some pharmacological treatments has been debated. In a systematic review of  
4 pharmacological CPSP interventions, Amitriptyline and Lamotrigine were found to be the only  
5 oral drugs to provide effective CPSP symptom alleviation but they may also result in  
6 unpleasant side effects[24].

7 Alongside pharmacological interventions, patients with CPSP have also been treated with  
8 neuromodulation therapy, physical therapy, and psychological therapy[66,77] with varied  
9 effectiveness. The most common neuromodulation techniques for CPSP, invasive Deep Brain  
10 Stimulation (DBS) and non-invasive repetitive Transcranial Magnetic Stimulation (rTMS),  
11 have mixed effectiveness rates[77,33]. Physical therapy is less common but mirror therapy and  
12 acupuncture have been trialled for CPSP treatment[15,18,89]. Finally, cognitive behaviour  
13 therapy (CBT) has been prescribed in some instances to help with psychological comorbidity  
14 of CPSP[10]. While some clinicians favour one type of therapy over another, treatments are  
15 often prescribed together in varying combinations. Literature reviews and guidelines of CPSP  
16 treatments are either small in scale, outdated, or focus on a single treatment modality[14,24,77].  
17 Systematic reviews and meta-analysis are also few and limited. Therefore, this systematic  
18 review and meta-analysis will build on the existing literature to provide a comprehensive  
19 review of CPSP treatment and research studies. The specific aims of this paper will be to (1)  
20 collate and describe available neuromodulating, pharmacological, physical and psychological  
21 treatments, (2) determine effectiveness of each treatment type, (3) and compare effectiveness  
22 of therapies within each treatment type.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 2 Methods

### 2.1 Protocol Registration

This review paper followed Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)<sup>63</sup>. The protocol of this review was registered with PROSPERO prior to literature review (CRD42022371835)[83].

### 2.2 Data sources and Searches

A systematic search of electronic databases was undertaken for interventional studies without a set time period with the primary or secondary outcome being reduction in pain for CPSP patients. A full breakdown of databases and journals for hand searching is provided in *Table 1*.

The search terms used in the study were formulated using Patient, Intervention, Comparison, and Outcome (PICO) framework[32]. Different wordings or treatment methods within a treatment type were combined using the “OR” operator. The sample and phenomenon of interest key words related to different names of CPSP (“Central Post\*Stroke Pain”, “Chronic Post\*Stroke Pain”, “Thalamic Pain”, “Dejerine\*Roussy syndrome”) and were combined using “AND” operator with design and evaluation terms relating to each treatment type: brain modulating (“Brain modulation”, “Neuromodulation”, “Repetitive Transcranial Magnetic Stimulation”, “TMS”, “rTMS”, “Deep Brain Stimulation”, “DBS”, “Vestibular Stimulation”) pharmacological (“pharmacological”, “Antidepressant”, “Anticonvulsant”, “Opioid”), physical (“Physical”, “Virtual Reality”, “VR”, “Physiotherapy”, “Acupuncture”) and psychological treatments (“Psychological”, “Mindfulness”, “Cognitive Behaviour Therapy”, “CBT”). References of all included papers were searched for any additional studies.

### 2.3 Study Selection

All identified studies were collated using Rayyan[70] systematic review management tool. Titles and abstracts for all studies (n = 5565) were blindly and independently screened by two reviewers (AT and BSP). Any conflict cases were consulted and resolved with a third reviewer (AM). Interrater reliability was calculated using Cohen’s Kappa score.

The inclusion criteria for type of studies to be included were: (1) randomised and non-randomised trials, (2) longitudinal and cross-sectional studies, (3) within and between group controls. The exclusion criteria for the type of studies were: (1) qualitative studies, (2) case studies, (3) reviews, (4) book chapters or articles, (5) animal studies, (6) dissertations, (7) abstract only articles, (8) papers in non-English language, and (9) grey literature. For grey literature pieces which could fit the inclusion criteria, authors were contacted for details of publications. Studies which included multiple chronic pain conditions were included, granted that data relating specifically to CPSP participants was extractable. Studies were excluded if dosage was not disclosed, virtual reality (VR) environments were not defined, or neuromodulation parameters not stated.

Studies were first title screened and then abstract screened. Studies that did not meet the inclusion and exclusion criteria were removed, and the remaining studies were subjected to a full text review. Studies which used “thalamic pain” or “post stroke pain” were reviewed with the third reviewer (AM) to confirm whether the condition was CPSP or a different neuropathic pain condition.

## 2.4 Data Extraction

1 Once final papers for inclusion were agreed on, a data extraction tool was created by reviewers  
2 using Microsoft (US) Excel[61]. Data extraction included mean VAS score change, percentage  
3 VAS score change, standard deviations (SD), confidence intervals, and demographic  
4 information. Where studies reported multiple outcome timepoints, VAS score change for the  
5 last time point was used. Details of all variables extracted from articles are presented in *Table*  
6 *2*.  
7  
8

9 For studies which did not report standard deviation, mean VAS change or mean percentage  
10 change, authors were contacted for information. Out of 15 studies, 6 had listed expired contact  
11 information and 7 contacted authors did not respond. Where only an SD score was missing, it  
12 was imputed using other available metrics and statistical calculations outlined in Cochrane  
13 Handbook for Systematic Reviews of Interventions[29]. Where a mean was not reported but  
14 all VAS score or percentage means were provided in the paper, the mean and SD were  
15 calculated by reviewers (AT and SL) following a systematic review methodology paper[92].  
16 Studies which had multiple treatment methods or groups with sufficiently different approaches,  
17 such as rTMS studies with different target locations or different medications covered in one  
18 study, were divided for meta-analysis using calculations from Cochrane Handbook[92]. The  
19 approach of splitting the sample size of the main group into multiple groups with smaller  
20 sample sizes was adopted for this. Other approaches were considered, such as combining  
21 treatment groups into one, but in the interest of covering as many treatment methodologies as  
22 possible, these approaches were not adopted.  
23  
24  
25  
26  
27  
28

## 2.5 Quality and Risk Assessment

29 All studies were quality and risk of bias assessed by two reviewers blindly and independently  
30 (AT and SL). Cross sectional studies which were not randomised trials were assessed using the  
31 Newcastle-Ottawa Scale (NOS)[93]. Randomised control trials and crossover trials were  
32 assessed using a revised Cochrane risk-of-bias tool (RoB 2)[30] and a RoB 2 tool for crossover  
33 trials respectively<sup>31</sup>. The respective tools ensured that the quality and risk assessment is  
34 appropriate for the study methods.  
35  
36  
37  
38  
39

40 All studies were additionally scored using the GRADE framework[32] by two independent  
41 reviewers (AT and SL). Randomised controlled trials started with high confidence while all  
42 other studies started with low confidence. Studies were considered against PICO criteria on  
43 imprecision, indirectness, inconsistency, publication bias, and risk of bias (*Table 3*). For each  
44 criteria, the study could be downgraded up to 2 times. There were also three positive criteria  
45 which could increase the rating of the study: (1) whether different dosage was tested, (2)  
46 whether an effect size was calculated and reported, and (3) whether the study considered  
47 confounders.  
48  
49  
50

## 2.6 Meta Analysis

51 Data extraction revealed that only 12 studies reported VAS mean score difference and SD  
52 metrics for both intervention and comparator groups. This was a limitation that excluded 10  
53 studies from a random-effects model meta-analysis. As this is a field where there is a lack of  
54 rigorous comparative studies and summative CPSP treatment reviews, a proportional meta-  
55 analysis was conducted on studies that could not be included in the random-effects model. This  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

decision was based on a proportional meta-analysis guide[8] and existing proportional model meta-analysis studies[9,22,25].

Meta-analysis was performed on each treatment group: physical, pharmacological, and neuromodulating. All random-effects meta-analyses were run using R Project using meta library[75,78], while the proportional meta-analyses were run using OpenMeta software[72]. As there was variability in treatment types within each group, select subgroups of specific treatments were analysed. Only treatments with two or more studies were considered for a subgroup meta-analysis. Funnel plot and Egger’s test were performed on all meta-analyses to identify publication bias.

Effect sizes for all meta-analyses were interpreted using SMD and 95% Confidence Intervals. Findings from studies high in risk of bias and or having scored low on quality assessment were considered but these findings should be interpreted cautiously.

### 3 Results

#### 3.1 Results of the Search

The systematic database and journal search found 14233 articles. Once duplicates were deleted, 5565 unique studies were identified. After a review of the study titles, 4483 journal articles had their abstracts screened, and 509 of those were selected for full text review. There were 22 studies which resulted in conflicting reviewer opinions. The main conflict was ambiguity around CPSP patient diagnosis. After deliberation and consultation with a third reviewer (AM), it was decided to include 19 of those studies. The search was rerun after 6 months which resulted in one additional study being identified for inclusion. There were 7 studies that did not have CPSP-specific data but met all other inclusion criteria. Authors of these studies were contacted for data but only 1 provided it, while other studies were excluded[4,5,34,42,49,51,65]. Finally, 42 journal articles were identified which met all inclusion criteria. PRISMA flowchart of the review process is detailed in *Figure 1*. The interrater reliability for both reviewers was found to be Kappa = 0.645 (p = 0.04).

Out of the 42 studies, 12 were randomised control trials, 8 were randomised crossover trials, 5 were retrospective, and 18 were cross sectional interventions. There were 14 pharmacological intervention studies, 5 physical intervention studies, 25 neuromodulation studies, but no psychological interventions were found. Characteristics of studies which were included in either random-effects or proportional meta-analyses are reported in *Table 4*, full study characteristics are provided in *Supplementary Table 1*

#### 3.2 Risk of Bias and Certainty of Evidence

Risk of bias and certainty of evidence for individual studies included in either random-effects or proportional meta-analyses are presented in *Table 5*. The mean risk of bias rating for studies included in random-effects meta-analysis was “Some Concerns”, the mean risk rating for proportional meta-analysis studies was “Some Concerns”, and the mean risk rating for studies which were not included in meta-analyses was “Some Concern”. GRADE framework identified that random-effects meta-analysis included studies’ mean rating was “Moderate” certainty of evidence, proportional meta-analysis studies mean rating was “Low”, studies not included in meta-analyses had a mean rating of “Low”.

### 3.3 Demographics of Included CPSP Participants

1 There were a total of 1451 participants included across 42 studies with 1191 of those being  
2 CPSP participants. The mean reported age of CPSP participants was 58.39 with a range of 23  
3 to 82 years old. Out of the studies that reported CPSP participant gender, 58.76% (n = 597)  
4 were male and 41.24% (n = 419) were female. As only a small sample of studies reported  
5 participant race, this was omitted from data extraction.

### 3.4 Stroke Aetiology

6  
7  
8 Out of reported stroke aetiologies, 46.23% (n = 233) were ischemic and 53.77% (n = 271) were  
9 haemorrhagic. Most of the strokes were thalamic, making up 52.05% (n = 406) out of 780  
10 reported cases. Extra-thalamic strokes made up 36.79% (n = 287), cortical strokes 8.85% (n =  
11 69), and multimodal strokes 2.31% (n = 18) of reported cases. More specific distribution of  
12 stroke locations is illustrated in *Figure 2*, but the most common reported lesions were in the  
13 Thalamus, Brainstem and Putamen. Some studies did not specify the location of a stroke other  
14 than “Extra-Thalamic” or “Cortex”, and thus were labelled as “Undefined” (n = 86).

### 3.5 Specification of Pain

15  
16  
17  
18  
19  
20 The mean duration of pain symptoms was 32.37 months with a range of 1 to 190 months across  
21 included studies. The mean pre-treatment VAS score across studies was 69.04. Pain was  
22 located on left side of the body in 52.05% of participants (n = 152), right side of the body in  
23 47.26% of participant (n = 138), and in alternate sides in 0.69% (n = 2). Upper limb was the  
24 most common localization of pain with 30.92% (n = 175) of participants, hemibody pain was  
25 second most common with 30.39% (n = 172), lower limb pain was reported by 22.97% (n =  
26 130), face localized pain by 12.36% (n=70), and trunk by 3.36% (n = 19) of participants.  
27 Regarding abnormal pain sensations, 43.52% (n = 245) of participants reported allodynia,  
28 28.24% (n = 159) reported hyperalgesia, 11.19% (n = 63) reported spontaneous pain, 10.48%  
29 (n = 59) reported continuous pain, and 6.46% (n = 37) of participants reported hypoesthesia.  
30 The most common quality of pain reported was burning which was reported by 49.03% (n =  
31 126) of participants, the second most common quality was tingling in 10.12% (n = 26), and  
32 third most common being tearing in 8.95% (n = 23) of participants. Full breakdown of reported  
33 qualities of pain is presented in *Figure 3*.

### 3.6 Neuromodulation Interventions

#### 3.6.1 Random-Effects Meta-Analysis

34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000



1 A sub-group analysis of all rTMS studies (n = 76) found a small to medium effect size for mean  
2 VAS reduction (SMD -0.46, 95% CI -0.97 to 0.04, I<sup>2</sup> 27.5%). Funnel plot showed symmetrical  
3 spread, and Egger's test was not significant (p = 0.73). When only M1 targeting rTMS studies  
4 were included (n = 55), the effect size was medium (SMD -0.68, 95% CI -1.22 to -0.13, I<sup>2</sup> 0%),  
5 but this analysis had high heterogeneity. Sub-group analysis of tDCS studies also found a  
6 medium effect size but high heterogeneity (SMD -0.64, 95% CI -1.35 to 0.008, I<sup>2</sup> 0%).

### 3.6.2 Proportional Meta-analysis

7 An analysis of 11 neuromodulation studies (n = 238), which included five rTMS, two Spinal  
8 Cord Stimulation (SCS), two Motor Cortex Stimulation (MCS), and two Deep Brain  
9 Stimulation (DBS) studies. On average, Pain outcome was measured over 6.09 time points with  
10 final follow up being 19.63 months after last intervention. The mean percentage reduction of  
11 mean VAS score across studies was 32.50% (CI 21.19 to 42.80, I<sup>2</sup> = 99.13%). There was  
12 considerable and significant heterogeneity among the studies, which is illustrated by a forest  
13 plot in *Figure 5*.  
14  
15  
16

17 A sub-group analysis of five rTMS studies found a reduction of mean VAS score by 26.50%  
18 with significant heterogeneity (CI 17.86 to 35.12, I<sup>2</sup> = 95.05%). Sub-group analysis of two M1  
19 DBS studies found a reduction of mean VAS score by 48.77% with low heterogeneity (CI  
20 47.53 to 50.01, I<sup>2</sup> = 0%). Sub-group analysis of two MCS studies found a reduction of mean  
21 VAS score by 34.90% with low heterogeneity (CI 25.52 to 44.28, I<sup>2</sup> = 0%). Sub-group analysis  
22 of two SCS studies found a reduction of mean VAS score by 27.00% with low heterogeneity  
23 (CI 19.17 to 34.84, I<sup>2</sup> = 0%).  
24  
25  
26

### 3.6.3 Narrative Summary

27 There were four rTMS studies which were not included in either meta-analysis. Across these  
28 studies, outcomes were measured, on average, over 10.25 time points with final follow up being  
29 0.46 months after last intervention. Khedr[41] is a placebo-controlled trial of rTMS over the  
30 primary motor cortex, but was not included in meta-analyses due to not reporting CPSP specific  
31 VAS reduction (n = 24), and instead reported all sample reduction (n = 48). It was reported that  
32 50% of all neuropathic pain patients achieved satisfactory (over 40%) VAS reduction 2 weeks  
33 after last session and 14.3% achieved good (over 70%) pain reduction. This was compared to  
34 the control group where 100% of neuropathic pain participants did not achieve satisfactory pain  
35 control. Kobayashi[46] performed a cross-sectional within subjects sham-controlled single  
36 blind study of rTMS over the motor cortex. Out of their 18 participants, 13 showed VAS  
37 percentage reduction of over 40% with 5 of those patients achieving over 79% reduction. The  
38 mean VAS reduction from 8<sup>th</sup> week of treatment to 12<sup>th</sup> weeks was 36.7 (SD = 21.1, p <0.01).  
39 McLean[60] performed a cross sectional rTMS study of 50 neuropathic pain participants, of  
40 which 5 had CPSP. After 6 weeks of stimulation CPSP participants reported a 53 point mean  
41 pain score decrease, but significance was not reported nor SD or metrics to impute SD were  
42 provided. The final study[27] performed a cross-sectional study of rTMS over primary motor  
43 cortex without a sham control (n = 14). The mean VAS score reduction was 7.00 or 10% on a  
44 101 point scale (p = 0.02). However, after 4 weeks the score increased by 3 points and was  
45 only a 3-point decrease from baseline and no longer significant (p = 0.17). Taking all rTMS  
46 studies into account, 66.07% (n = 37) out of 56 participants achieved satisfactory pain control  
47 as measured by over 40% VAS reduction.  
48  
49  
50  
51  
52  
53  
54  
55  
56

57 There were three cortex stimulation studies not included in the meta-analyses. Tsubokawa[86]  
58 performed a cross-sectional study without a control or sham group. Across these studies,  
59  
60  
61  
62  
63  
64  
65

1 outcomes were measured, on average, over 65.33 time points with final follow up being 20  
2 months after last intervention. Out of 11 participants, 9 achieved pain reduction of over 50%  
3 and 6 of those achieved pain reduction of over 80%. Longitudinal results showed that 45% of  
4 participants achieved pain control ( $p < 0.05$ ) over 2 months which is broken down to 5 patients  
5 maintaining over 80% of pain reduction, 1 participant having between 40% and 60% reduction,  
6 and 5 participants having less than 40% pain reduction. However, it was reported that tolerance  
7 to treatment developed within 7 months and good pain control reduced to only 38% of  
8 participants after 2 years. Yamamoto[97] study utilised cross sectional within-subjects  
9 comparative study of motor cortex stimulation versus pharmacological treatment. Monopolar  
10 square wave pulses were delivered to the motor cortex of 39 participants several times per day.  
11 Out of those participants, 13 were reported to have reduced pain by over 40% which was  
12 statistically significant ( $p < 0.05$ ). The final motor cortex stimulation study[40] investigated the  
13 effect of chronic motor cortex stimulation of 31 participants in a cross-sectional study without  
14 sham or control. Participants were tested for 1 week before implantation and 23 participants  
15 saw pain being reduced by over 40%. After implantation, 15 out of 23 participants maintained  
16 pain reduction of over 40%. Significance metric was not reported for these reductions. Overall,  
17 from 81 participants across MCS studies, 41.98% ( $n = 34$ ) achieved satisfactory pain control.  
18  
19

20 Yamamoto[98] performed a cross sectional within-subjects comparative study of spinal cord  
21 stimulation effectiveness versus pharmacological treatment. VAS mean pain was measured  
22 over 12 time points, with the last being 5 minutes after last injection. Of the 22 participants, 15  
23 received VAS score alleviation of over 30%, and 6 of those received pain alleviation of over  
24 60%. Significance was not reported for alleviation, but it significantly added to pain alleviation  
25 for ketamine treatment as add-on therapy. No side effects or other improvements were reported.  
26  
27  
28

### 29 **3.7 Secondary Outcomes and Side Effects**

30  
31 Out of all rTMS studies, Neuropathic Pain Inventory, Hamilton Depression Rating Scale  
32 (HAM-D) and Hamilton Anxiety Rating Scale (HAM-A) scores showed no significant  
33 improvement. Two rTMS studies[49,58] reported Patient Global Impression of Change (PGIC)  
34 improvement in 17 out of 34 participants across these studies. From 12 rTMS studies, 7  
35 reported side effects and across those studies, 16% ( $n = 32$ ) out of 200 reported mild adverse  
36 side effects, which included: increased pain, slight scalp discomfort, headache, dizziness,  
37 tiredness, paraesthesia, and facial muscle twitching. The most common side effects were  
38 transient increased pain ( $n = 6$ ), scalp discomfort ( $n = 5$ ), and headaches ( $n = 4$ ). There was 1  
39 moderate adverse event which was collapse.  
40  
41  
42

43 The one study on tDCS[6] reported that there were no significant differences in either cold  
44 sensation, warm sensation, cold pain or heat pain thresholds. No side effects were reported.  
45  
46

47 Vestibular Stimulation study[59] did not report any secondary outcome improvements or side  
48 effects. Two SCS studies[62,98] did not report any secondary outcomes, but did report an  
49 interaction of age and stroke location – younger participants and participants with thalamic  
50 stroke were more likely to respond to treatment. No side effects were reported for either study.  
51  
52

53 From all 5 MCS studies, only one study reported secondary outcomes[26]. They found that  
54 MCS significantly improved Pittsburgh Sleep Quality Index score from mean 16.38 score to  
55 mean 13.95 score. Side effects were reported in 3 MCS studies[40,86,97], and mild adverse  
56 events were seen in 3.70% ( $n = 3$ ) out of 81 participants: 1 participant had a postoperative  
57 infection, 2 participants reported increased pain. There were 3 patients (3.70%) with  
58 generalised seizures when high-frequency pulses went above muscle contraction threshold.  
59  
60  
61  
62  
63  
64  
65

## 3.7 Pharmacological Interventions

### 3.7.1 Random-Effects Meta-Analysis

1 There were four pharmacological studies included in the random-effects meta-analysis (n =  
2 231): two anticonvulsant (Pregabalin) studies, one antidepressant (duloxetine) study, and one  
3 opioid (Naloxone) study. On average, Pain outcome was measured over 3.5 time points over  
4 15.53 months of intervention but long-term follow up was not carried out in any study.  
5 Pharmacological interventions were found to have a small effect on mean VAS score (SMD -  
6 0.36, 95% CI -0.68 to -0.03,  $I^2$  60%; *Figure 6*). Funnel plot showed symmetrical spread within  
7 95% CI, and Egger's test of heterogeneity was not significant ( $p = 0.60$ ). Overall risk of bias  
8 score was "Some Concerns" and certainty of evidence was moderate to high, which indicates  
9 that there is a consistent therapeutic effect. A sub-group analysis of two anticonvulsant studies  
10 found a smaller effect on VAS reduction than overall pharmacological intervention (SMD -  
11 0.31, 95% CI -0.78 to 0.15,  $I^2$  72.5%). This meta-analysis indicates considerable heterogeneity,  
12 contains only two studies and moderate certainty of evidence, so this effect is limited in  
13 interpretation.  
14  
15  
16  
17  
18

### 3.7.2 Proportional Meta-analysis

19 The analysis was conducted on three pharmacological studies (N = 71): two antidepressant  
20 studies and one study of Lidocaine delivered as Peripheral Nerve Block (PNB). Results showed  
21 that the total percentage reduction of mean VAS score was 58.33% (CI 36.51 to 80.15,  $I^2 =$   
22 84.23%). There was considerable and significant heterogeneity among the studies, which is  
23 illustrated by a forest plot in *Figure 7*. Across these studies, pain outcomes were measured over  
24 2 time points – before and after interventions – over, on average, 1.02 months of treatment.  
25 Choi<sup>15</sup>, was the only study with a long-term follow up at 1 month, which was the score used to  
26 calculate percentage pain reduction. Sub-group analysis of two antidepressant studies found a  
27 reduction of mean VAS score by 67.43% with significant considerable heterogeneity (CI 26.85  
28 to 108.02,  $I^2 = 91.25\%$ ).  
29  
30  
31  
32  
33  
34

### 3.7.3 Narrative Summary

35 There were two antidepressant studies which were not included in either meta-analysis due to  
36 not reporting SD metrics. Lampl[50] performed a randomised placebo-controlled double-blind  
37 trial of 39 participants treated with amitriptyline as prophylaxis to CPSP. After 3 weeks of  
38 titration of up to 75mg of Amitriptyline, 1 less participant developed CPSP in Amitriptyline  
39 group than the placebo group and the mean VAS score was 2.0 smaller in the intervention  
40 group. These findings were not significant. Leijon and Boivie[53] performed a randomised  
41 placebo-controlled crossover study of 15 participants treated with 75mg amitriptyline  
42 (antidepressant) and 800mg carbamazepine (anticonvulsant) on mean pain score. Each  
43 medication period had 28 VAS assessment time-points, but no longitudinal follow-up. After 4  
44 weeks, only amitriptyline had a sustained significant reduction of pain with 10 patients  
45 reporting reduced pain with a mean 5 point reduction from initial mean 47 point score.  
46  
47  
48  
49  
50  
51

52 There were five more anticonvulsant studies which could not be included in meta-analyses.  
53 Across these studies, pain assessments were taken, on average, over 14.4 time points over a  
54 treatment period of 2.95 months. No study measured longitudinal follow up scores.  
55 Jungehulsing[38] conducted a randomised placebo crossover double-blind trial of 42  
56 participants for levetiracetam as CPSP treatment. The mean levetiracetam dose was 2130mg  
57 but it did not have a significant effect on participant mean pain scores. Rahajeng[76] performed  
58 an observational study of 36 participants taking pregabalin for CPSP. After 12 weeks, 26  
59  
60  
61  
62  
63  
64  
65

1 participants had more than 26% mean pain reduction, which was a significant effect ( $p < 0.05$ ),  
2 and 6 of those participants had over 51% pain reduction. Kalita[39] investigated pregabalin  
3 and lamotrigine in a crossover 30 participant open-label design. The maximum dose of  
4 pregabalin at the end of 8 weeks was 600mg daily and lamotrigine dose was 200mg daily. Out  
5 of those participants, pain alleviation of over 50% was achieved by 19 participants with  
6 pregabalin ( $p < 0.0001$ ) and 16 with lamotrigine ( $p < 0.0001$ ). These studies would indicate  
7 that out of 66 participants across both Pregabalin studies, over 50% pain reduction was  
8 achieved in 37.88% ( $n = 25$ ) of participants. Petramfar[73] performed a retrospective review  
9 of 17 participants taking lamotrigine for CPSP. After 24 weeks, there was a significant mean  
10 pain score decrease by 24.1 points ( $p = 0.001$ ) from initial mean score of 68.20.  
11 Vestergaard[91] conducted a randomised placebo-controlled crossover double-blind trial of 30  
12 participants for lamotrigine as treatment for CPSP. The median initial pain score was 60 and  
13 the median pain score after treatment was reduced by -10 compared to placebo of increase by  
14 10. This was a significant reduction in pain scores ( $p = 0.02$ ), but the decision to report median  
15 rather than mean score was not described or justified.  
16

17 There was one anaesthetic study[68] which investigated the effectiveness of morphine,  
18 thiamylal and ketamine as compared to MCS and placebo saline. This was a cross sectional,  
19 within subjects design with 39 participants. Anaesthetics were titrated on different one-day  
20 sessions with washout periods. Morphine was injected up to 18mg, thiamylal was injected up  
21 to 250mg, and ketamine was injected up to 25mg. Effectiveness of each treatment was  
22 measured by the number of patients with reduced pain, which were: 8 for morphine, 22 for  
23 thiamylal, 11 for ketamine, and 13 for MCS. The percentage or mean reduction of pain was not  
24 reported.  
25  
26  
27  
28

### 29 **3.7.4 Secondary Outcomes and Side Effects**

30 A study of duloxetine intervention[43] was the only one to not report secondary outcomes. On  
31 the other hand, Mahesh[57] duloxetine study found a significantly increased PGIC score when  
32 compared to the placebo group. From 119 participants across both studies, side effects were  
33 seen in 36.13% ( $n = 43$ ). Reported symptoms included: nausea, agitation, somnolence,  
34 dizziness, and recurring vomiting. Studies of amitriptyline and carbamazepine[50,53] did not  
35 have a significant effect on depression scores. Across both studies, 64.81% ( $n = 35$ ) out of 54  
36 total participants reported mild reactions, which included tiredness, dry mouth, vertigo, and  
37 gait disturbances. Further 3.70% ( $n = 2$ ) reported undisclosed moderate side effects.  
38 Fluvoxamine was found to have a significant effect on the Self-rating Depression Scale with a  
39 7.7 point decrease ( $p < 0.01$ ) from initial 44.3. Out of 28 participants, 10.51% ( $n = 3$ ) withdrew  
40 due to side effects, but side effects of the remaining participants were not tracked. Across all  
41 antidepressant studies, 36.82% ( $n = 74$ ) out of 201 participants reported side effects.  
42  
43  
44  
45  
46

47 Levetiracetam was not found to have a significant effect on McGill Pain Questionnaire or Beck  
48 Depression Inventory. There were 34 counts of mild adverse events reported in levetiracetam  
49 intervention group: 11 reported tiredness, 8 reported pain increase, 7 reported dizziness, 4  
50 reported pruritus, and 4 reported headaches. There were 7 people who reported withdrawals  
51 from levetiracetam with symptoms of fatigue and pain increase. Pregabalin was found to  
52 significantly improve allodynia, HAM-A and sleep. However, out of 378 pregabalin  
53 participants across both studies[39,42], side effects were reported in 56.35% ( $n = 213$ ). These  
54 included: somnolence, tremor, sedation, dizziness, pedal oedema, peripheral oedema, blurred  
55 vision, weight gain, and irritability. Out of all side effects, 10 were moderate and 8 were severe.  
56 Withdrawal was not observed or recorded in any of these studies. Across 2 studies which  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 reported other improvements with lamotrigine treatment, it was found that HADS score,  
2 allodynia, sleep, and mood significantly improved. From the 3 lamotrigine  
3 studies[39,73,77,90], mild side effects were reported in 36.36% (n = 28) and moderate to severe  
4 side effects were reported in 7.79% (n = 6) out of 77 participants. These side effects included:  
5 skin rash, somnolence, dizziness, fatigue, nausea, severe headaches, and severe pain. Overall,  
6 anticonvulsant studies found 54.29% (n = 247) out of 455 participants experienced side effects.

7 From the study of anaesthetics[68], no secondary improvements were reported. Out of all  
8 treatments, ketamine was the only drug to induce side effects. 5.13% (n = 2) out of 39 people  
9 experienced transient abnormal sensations. From a study of opioid antagonist Naloxone[7], no  
10 secondary outcomes were reported. There were 3 participants (15%) out of 20 who reported  
11 adverse reactions: 1 with increased pain and 2 with substantial rise in pulse due to sweating,  
12 tremor, salivation and pain.  
13

14 A peripheral nerve block study[16] reported that patients who responded to PNB showed a  
15 significantly reduced impact of pain on ability to work, relations with other people, and non-  
16 significant improvements of mood (p = 0.10) and sleep (p = 0.06). No participants reported  
17 adverse effects other than some transient weakness and numbness that lasted up to 3 hours.  
18  
19

## 20 **3.8 Physical Interventions**

### 21 **3.8.1 Random-Effects Meta-Analysis**

22 An analysis of two physical acupuncture studies found to have a moderate effect on mean VAS  
23 score (SMD -0.55, 95% CI -1.28 to 0.18, I<sup>2</sup> 0%; *Figure 8*). Both studies only collected VAS  
24 scores once before and once after intervention over a mean of 0.39 months. Funnel plot showed  
25 symmetrical spread within 95% CI, but heterogeneity could not be reliably tested with 2  
26 studies. Overall risk of bias score was “High” and certainty of evidence was low to very low,  
27 which severely limits the interpretation of this analysis.  
28  
29

### 30 **3.8.2 Narrative Summary**

31 No physical intervention studies were included in the proportional meta-analysis. Simmonds  
32 and Shahrban[82] cross sectional sham controlled within subjects study exposed 12  
33 participants to either “hot world”, “snow world”, neutral stimuli, or no stimuli. “Hot world”  
34 included scenes of volcanoes, “snow world” included snowy mountains, and neutral stimuli  
35 consisted of alternating white pillars on a black background. “Hot” stimuli significantly  
36 decreased participant mean VAS score by 17 points on a 101 point scale (p = 0.01), “Cold”  
37 stimuli significantly decreased it by 17 points (p = 0.01), neutral stimuli showed a 3.8 point  
38 increase (p = 0.87), and no VR showed a 3.0 point increase. Pain scores were collected only  
39 twice – before and after intervention – on the same day. Other improvements included  
40 significant increased threshold to cold and heat stimuli. No side effects were reported.  
41  
42  
43  
44  
45  
46  
47  
48

### 49 **3.8.3 Secondary Outcomes and Side Effects**

50 Neither of the two acupuncture studies reported any secondary improvements[15,95]. Across  
51 both studies, only 1 person (3.70%) out of 27 experienced side effects from acupuncture who  
52 left the study due to itching. Virtual reality[82] was found to significantly increase threshold  
53 to cold and heat stimuli. No side effects were reported.  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 4.1 Discussion

1 This systematic review and meta-analysis set out to review 4 different intervention types:  
2 pharmacological, physical, psychological, and neuromodulation. However, no psychological  
3 intervention studies for CPSP patients were found in this review. There were 15  
4 pharmacological, 3 physical, and 24 neuromodulation intervention studies. Stroke lesion  
5 causes were about equally distributed between ischemic and haemorrhagic. The most common  
6 reported stroke lesion location was thalamus, with brainstem and putamen as second most  
7 common locations, but this may be due to older studies focusing on thalamic origin pain.  
8 Duration of CPSP varied greatly from 1 month to 190 months, but the average was around  
9 32.57 months. Time from stroke until CPSP onset was rarely reported across studies.  
10 Lateralization of pain was evenly divided between the right and left side of the body.  
11 Hemibody, upper limb, lower limb, and face were the most common areas of pain. Allodynia  
12 was the most commonly reported pain characterization, followed by hyperalgesia and  
13 spontaneous pain. Mean VAS score before treatment for CPSP participants was 69.04, with  
14 most patients reporting the pain as “burning”, which was the most common descriptor and used  
15 almost 5 times more than the next most common descriptors: “tingling” or “tearing”.

19 From investigation of random-effects meta-analyses, neuromodulation was the most effective  
20 treatment with a moderate effect size, followed by physical interventions with moderate effect  
21 size, and pharmacological interventions with a small effect size. However, physical studies  
22 were limited by high risk of bias and low level of certainty<sup>15,82,95</sup>. Sub-group analysis of rTMS  
23 and tDCS found moderate effect sizes, whereas anticonvulsants were found to have a small  
24 effect size. The rTMS effect size was limited by one study<sup>5</sup> which applied rTMS to the  
25 premotor cortex and did not find a significant effect. Additionally, analysis of only rTMS  
26 interventions targeting M1 found the effect size to be higher than overall neuromodulation  
27 effect and slightly higher than tDCS, which supports the use of rTMS and tDCS as promising  
28 alternatives to invasive neuromodulation treatments[27,80,96]. The therapeutic action of  
29 modulating M1 is still being investigated, but could relate to inadvertent signalling of primary  
30 sensorimotor cortex (S1) or the potential pain pathway between M1 and S1[20]. Previous  
31 review articles[21,55,94,96] have pointed out a lack of standardised protocol for rTMS, but  
32 majority of the studies presented in this review adhere to 10-20Hz at 80-90% of motor  
33 threshold. There is not enough data to compare effectiveness at different frequencies, but future  
34 work is needed to clearly define the most optimal stimulation parameters.

41 Proportional meta-analyses were only performed on pharmacological and neuromodulation  
42 studies, as there were not enough physical studies for inclusion. Pharmacological interventions  
43 were found to be more effective than neuromodulation studies. However, significant  
44 heterogeneity of both meta-analyses reduces generalisability. Sub-group analysis found that  
45 antidepressants and DBS were the most effective in reducing VAS pain percentage in  
46 pharmacological and neuromodulation groups respectively. Conversely, a separate review of  
47 pharmacological CPSP treatments found gabapentin and pregabalin to be more effective[13],  
48 but the present review included a wider literature pool while some studies cited in Chen and  
49 Li[77] review could not be accessed in English. No other review articles have reliably  
50 compared pharmacological CPSP interventions, but animal research supports antidepressants  
51 as the most effective pharmacological treatment[81].

56 From narrative analyses, comparison of rTMS and MCS found that rTMS studies had more  
57 participants achieve satisfactory pain control at over 40%. The one SCS study[98] used 30%  
58 as a satisfactory control benchmark and, thus, cannot be effectively compared with rTMS or  
59

1 MCS. There was only one prophylactic study which found that Amitriptyline is not effective  
2 in preventing CPSP[50], but another study indicates that it could be used to reduce pain scores  
3 in CPSP patients[53]. Pregabalin was the most effective anticonvulsant in reducing mean pain  
4 score, followed by Lamotrigine, and Levetiracetam which had a non-significant effect. These  
5 findings are in line with findings from a recent post-stroke pain pharmacotherapies review  
6 which identified Pregabalin as the most effective treatment for CPSP[10]. A comparison of  
7 anaesthetic medication found that thiamylal was the most effective treatment when compared  
8 with ketamine or morphine. Only one physical study was identified[82] - a VR trial that  
9 demonstrated, immediately following treatment, significantly reduced mean VAS pain score  
10 and increased pain threshold for cold and heat stimuli. VR has been used in some capacity for  
11 post-stroke rehabilitation and chronic pain management, but is rarely used on CPSP  
12 patients[1,51,54]. Further research is needed to reliably understand VR effectiveness for CPSP,  
13 but it should be explored as a potential non-pharmacological and non-invasive add-on  
14 treatment.  
15

16 Secondary outcomes were only reported in select studies. Mood, anxiety or depression scores  
17 were not improved by rTMS, amitriptyline or carbamazepine. Amitriptyline[50] was only  
18 given for 3 weeks, which may not have been enough time to provide full effects, while the  
19 carbamazepine trial[53] reported that participants had low baseline depression scores.  
20 Fluvoxamine[79], Pregabalin[39,42,76], Lamotrigine[73], and MCS[26] all resulted in  
21 improvements in wellbeing through selective improvement of sleep, anxiety and depression  
22 scores. Peripheral nerve block had a significant effect on ability to work, but it is likely that  
23 this is due to a reduced pain score rather than the treatment itself. PGIC was only reported as  
24 significant in rTMS[27] and duloxetine studies[57], which might be confounded by the  
25 experience of rTMS, and mood stabilising properties of duloxetine. Improvement of allodynia  
26 was only reported in Lamotrigine[73], Pregabalin[39] and VR[82] interventions, but allodynia  
27 was rarely tested or reported across studies and further research is needed to understand how  
28 other interventions impact this symptom. Pregabalin and Lamotrigine effectiveness has been  
29 evidenced in literature, but VR is rarely explored for allodynia treatment[54,85,90]. Although,  
30 findings from this VR study would support the connection of VR as a tool to help control  
31 emotional feedback to pain which could moderate pain perception[88].  
32  
33

34 Virtual reality was the only intervention which had no side effects reported by participants.  
35 Acupuncture[15,95] and anaesthetics[97,98] had second least side effects reported, but these  
36 studies were limited by high risk of bias, low certainty of evidence, and small sample sizes.  
37 Acupuncture studies[15,95] were exclusively performed in East Asian countries where use and  
38 belief in acupuncture benefits are more widely accepted, which limits generalisation for  
39 populations in other countries. From least to most side effects reported interventions were:  
40 MCS, naloxone, rTMS, antidepressants, and anticonvulsants. MCS had the least amount of side  
41 effects measured over longest and most frequent follow-up times which indicates longitudinal  
42 pain relief, but it is an invasive and intensive procedure that should not be considered as  
43 primary intervention[55]. Antidepressants and rTMS were the only treatments with moderate  
44 adverse reactions, but they did not report any serious reactions. Anticonvulsant studies had the  
45 most reported side effects, but they had by far the largest sample which likely influenced side  
46 effect incidence. Anticonvulsant studies were also the only ones which had participants report  
47 withdrawal symptoms.  
48  
49

50 All things considered, antidepressants appear to be the most accessible treatment, particularly  
51 fluvoxamine, with a moderate effect on pain reduction, reported improvement in PGIC and  
52 mood, and least incidences of side effects and withdrawals. Anticonvulsants, particularly  
53  
54  
55  
56

1 Pregabalin, could be an alternative if antidepressants are not well tolerated or effective. This is  
2 followed by rTMS and tDCS as effective non-invasive neuromodulation interventions.  
3 Differences between rTMS and tDCS effectiveness for neuropathic pain has been explored in  
4 literature with findings suggesting close to equal performance with some preference for the  
5 former, but responders for either modality do not tend to overlap so both treatments should be  
6 trialled for pain alleviation[23,33,42]. Moreover, a recent review has suggested rTMS is a more  
7 advantageous treatment than pharmacological interventions due to a single-target mechanism  
8 that does not disrupt wider pathophysiological mechanisms[17]. The rTMS, MCS and DBS  
9 studies[11,26,41,52,56,58,67,71,84,99] included in this review primarily recruited participants  
10 who had medication refractory CPSP which illustrates the effectiveness of these interventions  
11 in reducing pain scores. Furthermore, a number of rTMS studies have shown effective  
12 neuropathic pain alleviation but were not included in this review as they did not report CPSP-  
13 specific data[6,68,69,95,100]. Anaesthetics included in this review also had good effectiveness  
14 and, while no side effects were reported, thiamylal[36], morphine[54] and ketamine[80] are  
15 known for possible serious adverse side effects, and, therefore, should only be considered for  
16 excruciating uncontrollable pain. Thiamylal and ketamine response does appear to predict  
17 MCS response, which could be used as a potential test prior to operation, but further research  
18 is needed to understand this interaction. Overall, MCS and DBS were found to have similar  
19 effectiveness and low number of side effects, but they are invasive treatments and CPSP  
20 patients should not consider this as a primary option for treatment. Virtual reality is a treatment  
21 that was only explored in one study, but it provided promising pain and physical improvements  
22 that should be explored in further studies. It could be a potential add-on therapy where  
23 equipment is available. Treatments that require further exploration with more robust  
24 methodology include SCS, acupuncture and PNB. Research into potential prophylactic  
25 treatments is also needed, as amitriptyline was not found to be effective.

#### 31 4.2 Other Limitations

32 The overall risk of bias score was “some concerns” and GRADE certainty of evidence showed  
33 that all included studies had a mean “low” score. Not regarding randomised controlled trials,  
34 there are issues in providing full reports on all relevant statistical metrics, disclosing full  
35 statistical analysis methodology, reporting side effects, and reporting withdrawal symptoms.  
36 VAS assessment scoring was also often not fully disclosed with just a mention that VAS score  
37 was taken, and some studies opted for different pain measurements which reduced comparison  
38 reliability. Session duration, session length, medication strength, follow-up length, and overall  
39 study length also increased heterogeneity and limited generalisability for group meta-analyses.  
40 While studies were grouped into either pharmacological, physical, or neuromodulation types  
41 for meta-analysis, there was considerable heterogeneity between some intervention modalities.  
42 Subgroup analyses provided supplementary validity to whole-group analyses.

43 There was also high variability in CPSP certainty across studies. Many studies did not perform  
44 additional assessments of participants, or relied solely on neuropathic pain questionnaires.  
45 However, good quality studies included in this review performed multiple assessments of  
46 stroke, exclusion of other conditions, and assessment of pain qualities. Some neuromodulation  
47 studies which were performed on primarily thalamic stroke patients, may need to be reassessed  
48 with a sample of wider stroke aetiologies. This forms part of a wider group data limitation and  
49 strategies to individualise treatments may result in improvements in outcomes.



### 4.3 Conclusions

1 While there have been other literature reviews and meta-analyses of CPSP treatments[37,94],  
2 they either had a focus on just one intervention modality, were smaller in literature search  
3 scope, or included only RCT studies[64,37,94]. This review is the most comprehensive  
4 overview of different treatment modalities available for CPSP with 16 different treatments in  
5 42 original studies investigating pharmacological, physical and neuromodulation interventions.  
6 Using three different analysis approaches – random-effects, proportional and narrative –  
7 allowed this review to collate and compare information from a large selection of intervention  
8 types and their effectiveness on CPSP pain reduction, secondary outcomes, and associated side  
9 effects. While overall quality of studies was moderate to low, there were a number of high  
10 quality controlled trials that provide a limited understanding of how different treatments  
11 compare. Future research should focus on conducting large sample randomised controlled trials  
12 to better understand effectiveness and potential side effects. There is also a lack of longitudinal  
13 studies, whether it is randomised controlled trials or retrospective reviews, to understand  
14 whether pain control is maintained in the long term and whether it improves over a longer  
15 period of time. It is hoped that findings of this review will provide guidance towards future  
16 CPSP treatment research and development of a more standardised treatment approach.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Acknowledgments

The authors extend a thank you to the Medical Research Council and Discovery Medicine North (DiMeN) doctoral training programme for funding this research.

There are no conflicts of interest.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## References

1. Ahmadpour, N., Randall, H., Choksi, H., Gao, A., Vaughan, C., & Poronnik, P. (2019). Virtual Reality interventions for acute and chronic pain management. *The international journal of biochemistry & cell biology*, *114*, 105568. <https://doi.org/10.1016/j.biocel.2019.105568>
2. Andersen, G., Christrup, L., & Sjøgren, P. (2003). Relationships among morphine metabolism, pain and side effects during long-term treatment: an update. *Journal of pain and symptom management*, *25*(1), 74-91. [https://doi.org/10.1016/S0885-3924\(02\)00531-6](https://doi.org/10.1016/S0885-3924(02)00531-6)
3. André-Obadia, N., Hodaj, H., Hodaj, E., Simon, E., Delon-Martin, C., & Garcia-Larrea, L. (2023). Better fields or currents? a head-to-head comparison of transcranial magnetic (rtms) versus direct current stimulation (tdcs) for neuropathic pain. *Neurotherapeutics*, *20*(1), 207-219. <https://doi.org/10.1007/s13311-022-01303-x>
4. André-Obadia, N., Magnin, M., & Garcia-Larrea, L. (2021). Theta-burst versus 20 Hz repetitive transcranial magnetic stimulation in neuropathic pain: A head-to-head comparison. *Clinical Neurophysiology*, *132*(10), 2702-2710.
5. Andre-Obadia, N., Mertens, P., Lelekov-Boissard, T., Afif, A., Magnin, M., & Garcia-Larrea, L. (2014). Is Life better after motor cortex stimulation for pain control? Results at long-term and their prediction by preoperative rTMS. *Pain physician*, *17*(1), 53. <https://doi.org/10.1016/j.clinph.2021.05.022>
6. Bae, S. H., Kim, G. D., & Kim, K. Y. (2014). Analgesic effect of transcranial direct current stimulation on central post-stroke pain. *The Tohoku journal of experimental medicine*, *234*(3), 189-195.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
7. Bainton, T., Fox, M., Bowsher, D., & Wells, C. (1992). A double-blind trial of naloxone in central post-stroke pain. *Pain*, *48*(2), 159-162. [https://doi.org/10.1016/0304-3959\(92\)90052-D](https://doi.org/10.1016/0304-3959(92)90052-D)
8. Barker, T. H., Migliavaca, C. B., Stein, C., Colpani, V., Falavigna, M., Aromataris, E., & Munn, Z. (2021). Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence. *BMC Medical Research Methodology*, *21*(1), 1-9.
9. Barretti, P., Doles, J. V. P., Pinotti, D. G., & El Dib, R. (2014). Efficacy of antibiotic therapy for peritoneal dialysis-associated peritonitis: a proportional meta-analysis. *BMC infectious diseases*, *14*(1), 1-11.
10. Bo, Z., Jian, Y., Yan, L., Gangfeng, G., Xiaojing, L., Xiaolan, L., ... & Jian, W. (2022). Pharmacotherapies for central post-stroke pain: a systematic review and network meta-analysis. *Oxidative Medicine and Cellular Longevity*, 2022.
11. Boccard, S. G., Pereira, E. A., Moir, L., Aziz, T. Z., & Green, A. L. (2013). Long-term outcomes of deep brain stimulation for neuropathic pain. *Neurosurgery*, *72*(2), 221-231. <https://doi.org/10.1227/NEU.0b013e31827b97d6>
12. Bonifácio de Assis, E. D., Martins, W. K. N., de Carvalho, C. D., Ferreira, C. M., Gomes, R., de Almeida Rodrigues, E. T., ... & Andrade, S. M. (2022). Effects of rTMS and tDCS on neuropathic pain after brachial plexus injury: A randomized placebo-controlled pilot study. *Scientific Reports*, *12*(1), 1440.
13. Chen, K. Y., & Li, R. Y. (2022). Efficacy and safety of different antidepressants and anticonvulsants in central poststroke pain: A network meta-analysis and systematic review. *Plos one*, *17*(10), e0276012. <https://doi.org/10.1371/journal.pone.0276012>

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
14. Cheng, Y., Wu, B., Huang, J., & Chen, Y. (2023). Research Progress on the Mechanisms of Central Post-Stroke Pain: A Review. *Cellular and Molecular Neurobiology*, 1-16.
  15. Cho, S. Y., Park, J. Y., Jung, W. S., Moon, S. K., Park, J. M., Ko, C. N., & Park, S. U. (2013). Bee venom acupuncture point injection for central post stroke pain: a preliminary single-blind randomized controlled trial. *Complementary therapies in medicine*, 21(3), 155-157. <https://doi.org/10.1016/j.ctim.2013.02.001>
  16. Choi, Y. H., Kim, D. H., Paik, N. J., & Park, J. (2021). Long- term analgesic effects of peripheral nerve block in patients with central post- stroke pain: A retrospective series. *Pain Practice*, 21(8), 843-849. <https://doi.org/10.1111/papr.13031>
  17. Ciampi de Andrade, D., & García- Larrea, L. (2023). Beyond trial- and- error: Individualizing therapeutic transcranial neuromodulation for chronic pain. *European Journal of Pain*.
  18. Corbetta, D., Sarasso, E., Agosta, F., Filippi, M., & Gatti, R. (2018). Mirror therapy for an adult with central post-stroke pain: a case report. *Archives of Physiotherapy*, 8(1), 1-6.
  19. de Oliveira, R. A. A., de Andrade, D. C., Mendonça, M., Barros, R., Luvisoto, T., Myczkowski, M. L., Marcolin, M. A., & Teixeira, M. J. (2014). Repetitive transcranial magnetic stimulation of the left premotor/dorsolateral prefrontal cortex does not have analgesic effect on central poststroke pain. *The Journal of Pain*, 15(12), 1271-1281.
  20. Delon-Martin, C., Lefaucheur, J. P., Hodaj, E., Sorel, M., Dumolard, A., Payen, J. F., & Hodaj, H. (2023). Neural correlates of pain-autonomic coupling in patients with complex regional pain syndrome treated by repetitive transcranial magnetic stimulation of the motor cortex. *Neuromodulation: Technology at the Neural Interface*.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
21. DosSantos, M. F., Ferreira, N., Toback, R. L., Carvalho, A. C., & DaSilva, A. F. (2016). Potential mechanisms supporting the value of motor cortex stimulation to treat chronic pain syndromes. *Frontiers in neuroscience, 10*, 18.
  22. Efthymiadis, A., Tsikopoulos, K., Uddin, F., Kitridis, D., Edwards, N., Sidiropoulos, K., & Lavalette, D. (2022). Which is the optimal minimally invasive treatment for osteoid osteoma of the hip? A systematic review and proportional meta-analysis. *Journal of Orthopaedic Science, 27*(2), 456-462.
  23. Forogh, B., Haqiqatshenas, H., Ahadi, T., Ebadi, S., Alishahi, V., & Sajadi, S. (2021). Repetitive transcranial magnetic stimulation (rTMS) versus transcranial direct current stimulation (tDCS) in the management of patients with fibromyalgia: A randomized controlled trial. *Neurophysiologie Clinique, 51*(4), 339-347.
  24. Frese, A., Husstedt, I. W., Ringelstein, E. B., & Evers, S. (2006). Pharmacologic treatment of central post-stroke pain. *The Clinical journal of pain, 22*(3), 252-260.
  25. Frountzas, M., Stergios, K., Nikolaou, C., Bellos, I., Schizas, D., Linardoutsos, D., ... & Toutouzas, K. (2020). Could FiLaC™ be effective in the treatment of anal fistulas? A systematic review of observational studies and proportional meta- analysis. *Colorectal Disease, 22*(12), 1874-1884.
  26. Guo, S., Zhang, X., Tao, W., Zhu, H., & Hu, Y. (2022). Long- term follow- up of motor cortex stimulation on central poststroke pain in thalamic and extrathalamic stroke. *Pain Practice, 22*(7), 610-620.
  27. Hasan, M., Whiteley, J., Bresnahan, R., MacIver, K., Sacco, P., Das, K., & Nurmikko, T. (2014). Somatosensory change and pain relief induced by repetitive transcranial magnetic stimulation in patients with central poststroke pain. *Neuromodulation: Technology at the Neural Interface, 17*(8), 731-736.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
28. Henry, J. L., Lalloo, C., & Yashpal, K. (2008). Central poststroke pain: an abstruse outcome. *Pain Research and Management*, *13*, 41-49.
29. Higgins, J. P., & Green, S. (Eds.). (2008). *Cochrane handbook for systematic reviews of interventions*.
30. Higgins, J. P., Altman, D. G., Gøtzsche, P. C., Jüni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., & Sterne, J. A. (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *Bmj*, *343*.
31. Higgins, J. P., Li, T., & Sterne, J. (2021). Revised Cochrane risk of bias tool for randomized trials (RoB 2) Additional considerations for crossover trials.
32. Higgins, J. P., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., Welch, V. A. (2022). *Cochrane Handbook for Systematic Reviews of Interventions* version 6.3 (updated February 2022). *Cochrane*, 2022. Available from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).
33. Hosomi, K., Seymour, B., & Saitoh, Y. (2015). Modulating the pain network—neurostimulation for central poststroke pain. *Nature Reviews Neurology*, *11*(5), 290-299.
34. Hosomi, K., Shimokawa, T., Ikoma, K., Nakamura, Y., Sugiyama, K., Ugawa, Y., ... & Saitoh, Y. (2013). Daily repetitive transcranial magnetic stimulation of primary motor cortex for neuropathic pain: a randomized, multicenter, double-blind, crossover, sham-controlled trial. *PAIN®*, *154*(7), 1065-1072.
35. Huygelier, H., Mattheus, E., Abeele, V. V., Van Ee, R., & Gillebert, C. R. (2021). The use of the term virtual reality in post-stroke rehabilitation: a scoping review and commentary. *Psychologica Belgica*, *61*(1), 145.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
36. Irie, S., Hirai, K., Kano, K., Yanabe, S., & Migita, M. (2020). Efficacy and safety of intravenous thiamylal in pediatric procedural sedation for magnetic resonance imaging. *Brain and Development*, 42(7), 477-483.
37. Joseph, A. M., Karas, M., Silva, C. E. J., Leyva, M., Salam, A., Sinha, M., ... & Leyva, M. M. (2023). The Potential Role of Etanercept in the Management of Post-stroke Pain: A Literature Review. *Cureus*, 15(3).
38. Jungehulsing, G. J., Israel, H., Safar, N., Taskin, B., Nolte, C. H., Brunecker, P., ... & Villringer, A. (2013). Levetiracetam in patients with central neuropathic post- stroke pain— a randomized, double- blind, placebo- controlled trial. *European Journal of Neurology*, 20(2), 331-337.
39. Kalita, J., Chandra, S., & Misra, U. K. (2017). Pregabalin and lamotrigine in central poststroke pain: A pilot study. *Neurology India*, 65(3), 506.
40. Katayama, Y., Fukaya, C., & Yamamoto, T. (1998). Poststroke pain control by chronic motor cortex stimulation: neurological characteristics predicting a favorable response. *Journal of neurosurgery*, 89(4), 585-591.
41. Khedr, E. M., Kotb, H., Kamel, N. F., Ahmed, M. A., Sadek, R., & Rothwell, J. C. (2005). Longlasting antalgic effects of daily sessions of repetitive transcranial magnetic stimulation in central and peripheral neuropathic pain. *Journal of Neurology, Neurosurgery & Psychiatry*, 76(6), 833-838.
42. Kim, J. S., Bashford, G., Murphy, T. K., Martin, A., Dror, V., & Cheung, R. (2011). Safety and efficacy of pregabalin in patients with central post-stroke pain. *Pain*, 152(5), 1018-1023.



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
43. Kim, N. Y., Lee, S. C., & Kim, Y. W. (2019). Effect of duloxetine for the treatment of chronic central poststroke pain. *Clinical Neuropharmacology*, *42*(3), 73-76.
44. Klit, H., Finnerup, N. B., & Jensen, T. S. (2009). Central post-stroke pain: clinical characteristics, pathophysiology, and management. *The Lancet Neurology*, *8*(9), 857-868.
45. Klit, H., Finnerup, N. B., Andersen, G., & Jensen, T. S. (2011). Central poststroke pain: a population-based study. *PAIN®*, *152*(4), 818-824.
46. Kobayashi, M., Fujimaki, T., Mihara, B., & Ohira, T. (2015). Repetitive transcranial magnetic stimulation once a week induces sustainable long-term relief of central poststroke pain. *Neuromodulation: Technology at the Neural Interface*, *18*(4), 249-254.
47. Krause, T., Brunecker, P., Pittl, S., Taskin, B., Laubisch, D., Winter, B., ... & Jungehulsing, G. J. (2012). Thalamic sensory strokes with and without pain: differences in lesion patterns in the ventral posterior thalamus. *Journal of Neurology, Neurosurgery & Psychiatry*, *83*(8), 776-784.
48. Kumar, B., Kalita, J., Kumar, G., & Misra, U. K. (2009). Central poststroke pain: a review of pathophysiology and treatment. *Anesthesia & Analgesia*, *108*(5), 1645-1657
49. Lampl, C., Schweiger, C., Haider, B., & Lechner, A. (2010). Pregabalin as mono-or add-on therapy for patients with refractory chronic neuropathic pain: a post-marketing prescription-event monitoring study. *Journal of neurology*, *257*, 1265-1273.
50. Lampl, C., Yazdi, K., & Röper, C. (2002). Amitriptyline in the prophylaxis of central poststroke pain: preliminary results of 39 patients in a placebo-controlled, long-term study. *Stroke*, *33*(12), 3030-3032.
51. Lefaucheur, J. P., Drouot, X., Menard-Lefaucheur, I., Keravel, Y., & Nguyen, J. P. (2008). Motor cortex rTMS in chronic neuropathic pain: pain relief is associated with thermal

sensory perception improvement. *Journal of Neurology, Neurosurgery & Psychiatry*, 79(9), 1044-1049.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
52. Lefaucheur, J. P., Drouot, X., Menard-Lefaucheur, I., Zerah, F., Bendib, B., Cesaro, P., ... & Nguyen, J. P. (2004). Neurogenic pain relief by repetitive transcranial magnetic cortical stimulation depends on the origin and the site of pain. *Journal of Neurology, Neurosurgery & Psychiatry*, 75(4), 612-616.
53. Leijon, G., & Boivie, J. (1989). Central post-stroke pain—a controlled trial of amitriptyline and carbamazepine. *Pain*, 36(1), 27-36.
54. Li, A., Montaña, Z., Chen, V. J., & Gold, J. I. (2011). Virtual reality and pain management: current trends and future directions. *Pain management*, 1(2), 147-157.
55. Liampas, A., Velidakis, N., Georgiou, T., Vadalouca, A., Varrassi, G., Hadjigeorgiou, G. M., ... & Zis, P. (2020). Prevalence and management challenges in central post-stroke neuropathic pain: a systematic review and meta-analysis. *Advances in therapy*, 37, 3278-3291.
56. Lin, H., Li, W., Ni, J., & Wang, Y. (2018). Clinical study of repetitive transcranial magnetic stimulation of the motor cortex for thalamic pain. *Medicine*, 97(27).
57. Mahesh, B., Singh, V. K., Pathak, A., Kumar, A., Mishra, V. N., Joshi, D., & Chaurasia, R. N. (2023). Efficacy of Duloxetine in Patients with Central Post-stroke Pain: A Randomized Double Blind Placebo Controlled Trial. *Pain Medicine*, 24(6), 610-617.
58. Matsumura, Y. (2013). Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) of Primary Motor Cortex in Post-stroke Pain Patients. *International Journal of Oral-Medical Sciences*, 11(3), 194-201.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
59. McGeoch, P. D., Williams, L. E., Lee, R. R., & Ramachandran, V. S. (2008). Behavioural evidence for vestibular stimulation as a treatment for central post-stroke pain. *Journal of Neurology, Neurosurgery & Psychiatry*, 79(11), 1298-1301.
60. McLean, L. A., Frank, S., Zafar, N., Waschke, A., Kalff, R., & Reichart, R. (2018). Time course of the response to navigated repetitive transcranial magnetic stimulation at 10 Hz in chronic neuropathic pain. *Neurological research*, 40(7), 566-574.
61. Microsoft Corporation. (2018). Microsoft Excel. Retrieved from <https://office.microsoft.com/excel>.
62. Mohamed, M. A., Saitoh, Y., Hosomi, K., Oshino, S., Kishima, H., & Yoshimine, T. (2010). Spinal cord stimulation for central poststroke pain. *Operative Neurosurgery*, 67(3), ons206-ons212.
63. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & Prisma Group. (2010). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *International journal of surgery*, 8(5), 336-341.
64. Mulla, S. M., Wang, L., Khokhar, R., Izhar, Z., Agarwal, A., Couban, R., ... & Busse, J. W. (2015). Management of central poststroke pain: systematic review of randomized controlled trials. *Stroke*, 46(10), 2853-2860.
65. O'neill, F., Sacco, P., Bowden, E., Asher, R., Burnside, G., Cox, T., & Nurmikko, T. (2018). Patient-delivered tDCS on chronic neuropathic pain in prior responders to TMS (a randomized controlled pilot study). *Journal of pain research*, 3117-3128.
66. Oh, H., & Seo, W. (2015). A comprehensive review of central post-stroke pain. *Pain Management Nursing*, 16(5), 804-818.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
67. Ohn, S. H., Chang, W. H., Park, C. H., Kim, S. T., Lee, J. I., Pascual-Leone, A., & Kim, Y. H. (2012). Neural correlates of the antinociceptive effects of repetitive transcranial magnetic stimulation on central pain after stroke. *Neurorehabilitation and neural repair*, 26(4), 344-352.
68. Ojala, J., Vanhanen, J., Harno, H., Lioumis, P., Vaalto, S., Kaunisto, M. A., ... & Kalso, E. (2022). A randomised, sham-controlled trial of repetitive transcranial magnetic stimulation targeting M1 and S2 in central poststroke pain: a pilot trial. *Neuromodulation: Technology at the Neural Interface*, 25(4), 538-548.
69. Onouchi, K., Koga, H., Yokoyama, K., & Yoshiyama, T. (2014). An open-label, long-term study examining the safety and tolerability of pregabalin in Japanese patients with central neuropathic pain. *Journal of pain research*, 439-447.
70. Ouzzani, M., Hammady, H., Fedorowicz, Z., and Elmagarmid, A. [Rayyan — a web and mobile app for systematic reviews](#). *Systematic Reviews*, 210(2016) 5-210, DOI: 10.1186/s13643-016-0384-4.
71. Owen, S. L., Green, A. L., Stein, J. F., & Aziz, T. Z. (2006). Deep brain stimulation for the alleviation of post-stroke neuropathic pain. *Pain*, 120(1-2), 202-206.
72. Parrott, J. S. (2023). OpenMeta[Analyst]. Available from: <http://www.cebm.brown.edu/openmeta/index.html>
73. Petramfar, P., Nikseresht, A. R., & Yaghoubi, E. (2010). The effects of lamotrigine on pain, sleep, and mood in refractory form of central post-stroke pain syndrome.
74. Quesada, C., Pommier, B., Fauchon, C., Bradley, C., Créac'h, C., Murat, M., ... & Peyron, R. (2020). New procedure of high-frequency repetitive transcranial magnetic stimulation for

central neuropathic pain: a placebo-controlled randomised crossover study. *Pain*, 161(4), 718-728.

1  
2  
3 75. R Core Team (2021). R: A language and environment for statistical computing. Available  
4  
5 from: <https://www.R-project.org/>.

6  
7  
8  
9 76. Rahajeng, B., Ikawati, Z., Andayani, T. M., & Dwiprahasto, I. (2018). The effect of  
10 Pregabalin on the quality of life in patients with central post-stroke pain. *Journal of Young*  
11  
12 *Pharmacists*, 10(2), 222.

13  
14  
15  
16  
17 77. Ri, S. (2022). The Management of Poststroke Thalamic Pain: Update in Clinical Practice.  
18  
19 *Diagnostics*, 12(6), 1439.

20  
21  
22  
23 78. Schwarzer, G. (2023). General Package for Meta-Analysis version 6.5-0. Available from:  
24  
25 <https://github.com/guido-s/meta/>

26  
27  
28  
29 79. Shimodozono, M., Kawahira, K., Kamishita, T., Ogata, A., Tohgo, S. I., & Tanaka, N.  
30  
31 (2002). Brief clinical report reduction of central poststroke pain with the selective serotonin  
32  
33 reuptake inhibitor fluvoxamine. *International Journal of Neuroscience*, 112(10), 1173-  
34  
35 1181.

36  
37  
38  
39  
40 80. Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018). Side-effects associated  
41  
42 with ketamine use in depression: a systematic review. *The Lancet Psychiatry*, 5(1), 65-78.

43  
44  
45  
46 81. Shyu, B. C., He, A. B., Yu, Y. H., & Huang, A. C. W. (2021). Tricyclic antidepressants and  
47  
48 selective serotonin reuptake inhibitors but not anticonvulsants ameliorate pain, anxiety, and  
49  
50 depression symptoms in an animal model of central post-stroke pain. *Molecular Pain*, 17,  
51  
52 17448069211063351.

53  
54  
55  
56  
57 82. Simmonds, M. J., & Shahrbanian, S. (2008). Effects of different virtual reality environments  
58  
59 on experimental pain threshold in individuals with pain following stroke. *ICDVRAT 2008*.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
83. Tamasauskas, A., Marshall, A., Passadouro, B. S., Keller, S., Fallon, N., Frank, B. (2023). Management of Central Post-Stroke Pain: Systematic Review and Meta Analysis. *PROSPERO: International prospective register of systematic reviews*. Available from: [https://www.crd.york.ac.uk/prospero/display\\_record.php?ID=CRD42022371835](https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022371835)
84. Tanei, T., Kajita, Y., Takebayashi, S., Aoki, K., Nakahara, N., & Wakabayashi, T. (2019). Predictive factors associated with pain relief of spinal cord stimulation for central post-stroke pain. *Neurologia medico-chirurgica*, 59(6), 213-221.
85. Titlic, M., Jukic, I., Tonkic, A., Josipovic-Jelic, Z., Boschi, V., Mihalj, M., & Punda, A. (2008). Lamotrigine in the treatment of pain syndromes and neuropathic pain. *Bratislavske Lekarske Listy*, 109(9), 421-424.
86. Tsubokawa, T., Katayama, Y., Yamamoto, T., Hirayama, T., & Koyama, S. (1993). Chronic motor cortex stimulation in patients with thalamic pain. *Journal of neurosurgery*, 78(3), 393-401.
87. Urits, I., Gress, K., Charipova, K., Orhurhu, V., Freeman, J. A., Kaye, R. J., ... & Viswanath, O. (2020). Diagnosis, Treatment, and Management of Dejerine–Roussy Syndrome: a Comprehensive Review. *Current Pain and Headache Reports*, 24, 1-9.
88. Ushida, T., Ikemoto, T., Taniguchi, S., Ishida, K., Murata, Y., Ueda, W., ... & Tani, T. (2005). Virtual pain stimulation of allodynia patients activates cortical representation of pain and emotions: a functional MRI study. *Brain topography*, 18, 27-35.
89. Veerbeek, J. M., van Wegen, E., van Peppen, R., van der Wees, P. J., Hendriks, E., Rietberg, M., & Kwakkel, G. (2014). What is the evidence for physical therapy poststroke? A systematic review and meta-analysis. *PloS one*, 9(2), e87987.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
90. Verma, V., Singh, N., & Singh Jaggi, A. (2014). Pregabalin in neuropathic pain: evidences and possible mechanisms. *Current neuropharmacology*, 12(1), 44-56.
91. Vestergaard, K., Andersen, G., Gottrup, H., Kristensen, B. T., & Jensen, T. S. (2001). Lamotrigine for central poststroke pain: a randomized controlled trial. *Neurology*, 56(2), 184-190.
92. Weir, C. J., Butcher, I., Assi, V., Lewis, S. C., Murray, G. D., Langhorne, P., & Brady, M. C. (2018). Dealing with missing standard deviation and mean values in meta-analysis of continuous outcomes: a systematic review. *BMC medical research methodology*, 18(1), 1-14.
93. Wells, G. A., Shea, B., O'Connell, D., Peterson, J., Welch, V., Losos, M., & Tugwell, P. (2000). The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.
94. Wu, L. N., Zheng, H. Y., Xue, S. A., Chen, K. Y., & Li, R. Y. (2023). The Efficacy and Safety of Different Noninvasive Therapies in the Treatment of Central Poststroke Pain (CPSP): A Network Meta-Analysis and Systematic Review. *Journal of Integrative Neuroscience*, 22(4), 102.
95. Xiao-Nong, F., Zhang, X., Wu, L. Z., & Wang, H. R. (2012). Clinical efficacy observation of thalamic pain treated with acupuncture under the guidance of evidence-based medicine. *World Journal of Acupuncture-Moxibustion*, 22(3), 1-17.
96. Xu, X. M., Luo, H., Rong, B. B., Zheng, X. M., Wang, F. T., Zhang, S. J., & Li, Z. X. (2020). Nonpharmacological therapies for central poststroke pain: a systematic review. *Medicine*, 99(42).

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
97. Yamamoto, T., Katayama, Y., Hirayama, T., & Tsubokawa, T. (1997). Pharmacological classification of central post-stroke pain: comparison with the results of chronic motor cortex stimulation therapy. *Pain*, 72(1-2), 5-12.
98. Yamamoto, T., Watanabe, M., Obuchi, T., Kano, T., Kobayashi, K., Oshima, H., ... & Yoshino, A. (2016). Importance of pharmacological evaluation in the treatment of poststroke pain by spinal cord stimulation. *Neuromodulation: Technology at the Neural Interface*, 19(7), 744-751.
99. Zhang, X., Zhu, H., Tao, W., Li, Y., & Hu, Y. (2018). Motor cortex stimulation therapy for relief of central post-stroke pain: a retrospective study with neuropathic pain symptom inventory. *Stereotactic and Functional Neurosurgery*, 96(4), 239-243.
100. Zhao, C. G., Sun, W., Ju, F., Jiang, S., Wang, H., Sun, X. L., ... & Yuan, H. (2021). Analgesic effects of navigated repetitive transcranial magnetic stimulation in patients with acute central poststroke pain. *Pain and Therapy*, 10, 1085-1100.



## Tables

Table 1: Searched Databases and Journals

<b>Databases</b>	<b>Journals</b>
CINAHL	Disability and Rehabilitation
Cochrane	Patient Education and Counselling
Frontiers	International Journal of Stroke
Google Scholar	Journal of Neurology
PsycINFO	Journal of Pain
PubMed	Journal of Pain and Symptom Management
Sage	Journal of Stroke and Cerebrovascular Diseases Neurosurgery and Psychiatry
Springer	Journal of Stroke
Taylor and Francis	Journal of Pain Research
Web of Science	

Table 2: Information variables extracted from included studies

---

**Variables Extracted**

---

1  
2 Area of pain

3  
4 Blinding procedure

5  
6  
7 Demographic characteristics of participants

8  
9 Design of the study

10  
11 Intervention type and current/dosage strength

12  
13 Other non-pain improvements

14  
15 Pain outcome measure

16  
17 Pain scores before and after intervention

18  
19 Reduction in pain score

20  
21 Participant recruitment procedures

22  
23 Relevant statistical information

24  
25 Sample size

26  
27 Side effects or withdrawal symptoms

28  
29 Stroke aetiology

30  
31 Time since stroke or CPSP onset

---

Table 3: GRADE Framework Negative Criteria

GRADE Domain	Journals
Population	How certain is participants' CPSP diagnosis?
Population	Was recruitment of participants explained well?
Intervention	Does the intervention sequence follow best practice?
Intervention	Was the blinding procedure adequate?
Comparison	Was demographic data between participants not significantly different?
Comparison	Was there placebo control?
Outcomes	Were side effects reported?
Outcomes	Would further evidence change our confidence in the estimate of effect?
Imprecision	Was the sample sufficiently large enough for statistical power?
Imprecision	Were statistical assumptions checked before analysis?
Indirectness	Were pain measures thoroughly explained?
Inconsistency	Is the reporting of results consistent?
Publication Bias	Was there Conflict of Interest or Industry sponsorship?
Risk of Bias	Is the estimated risk of bias high?

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

*Table 4 Study Characteristics; Random-Effects meta-analysis in grey, and proportional meta-analysis in white*

<b>Study ID</b>	<b>Methodology</b> <b>T: Type</b> <b>C: Control</b> <b>B: Blinding</b>	<b>Intervention</b> <b>T: Type</b> <b>S: Specific Treatment</b> <b>C: Control/Sham type</b>	<b>Treatment Specificity</b> <b>S: Strength</b> <b>A: Administration</b> <b>D: Duration</b>	<b>Participants</b> <b>T: Total</b> <b>C: CPSP patients</b>	<b>Demographics</b> <b>A: CPSP patient age in years mean (SD/range)</b> <b>G: Gender, N; Male (Female)</b> <b>C: CPSP duration months (SD/range)</b>	<b>Reported outcome measures</b> <b>A: Pain</b> <b>B: Psychological</b> <b>C: Physical</b>
Bae, 2014[6]	T: Randomised trial C: Sham trial B: Single	T: Neuromodulation S: tDCS <sup>A</sup> C: Current only applied for 30 seconds	S: 2mA A: M1 <sup>B</sup> D: 3 times per week for 3 weeks	T: 14 C: 14	A: 51.70 (RI*) G: 7 (7) D: 14.6 (RI)	A: VAS <sup>1</sup> : B: NR** C: Skin temperature, QST <sup>2</sup>
Bainton, 1992[7]	T: Randomised trial C: Crossover B: Double	T: Pharmacological S: Naloxone C: Saline	S: 8mg A: Injection D: 45 min to 190 min	T: 20 C: 20	A: 61.10 (45 – 74) G: 7 (13) D: NR	A: BPI <sup>3</sup> B: NR C: NR

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Cho, 2013[15]	T: Randomised trial C: Placebo-control B: Single	T: Physical S: Bee venom acupuncture C: Saline injection in to 1 acupoint	S: 0.05ml diluted bee venom A: acupoints of affected side D: Once	T: 16 C: 16	A : NR (36 - 88) G: NR D: NR	A: VAS B: NR C: NR
De Oliveira, 2014[19]	T: Randomised trial C: Sham-control B: Double	T: Neuromodulation S: rTMS <sup>C</sup> C: Identical sham coil emitting sound	S: 1250 pulses at 10 Hz, 50% MT <sup>D</sup> A: Premotor cortex D: RI	T: 21 C: 21	A: 56.33 ( 10.59) G: 11 (10) D: 57.40 (50.24)	A: VAS, NPS <sup>4</sup> B: HAM-A <sup>5</sup> , HAM-D <sup>6</sup> C: NR
Kim, 2011[42]	T: Randomised trial C: Placebo control B: Double	T: Pharmacological S: Pregabalin C: Placebo pill	S: Mean 356.8 mg (125 – 539.70) A: Daily pill D: 4 weeks	T: 219 C: 219	A: 58.28 (RI) G: 137 (82) D: 28.2 (1.20 – 212.40)	A: VAS B: HADS <sup>7</sup> C: NR
Mahesh, 2022[57]	T: Randomised C: Placebo control B: Double	T: Pharmacological S: Duloxetine C: Placebo pill	S: 30mg to 60mg (based on NRS <sup>8</sup> pain intensity at 2 weeks) A: Daily pill D: 4 weeks	T: 82 C: 82	A: 55.80 (9.90) G: 47 (35) D: 2 (6.67 - 48)	A: NRS, SF-MPQ <sup>9</sup> , PDI <sup>10</sup> B: PGIC <sup>11</sup> C: NR
McGeoch, 2008[59]	T: Cross sectional Within-subject C: Sham-control B: Single	T: Neurostimulation S: Vestibular stimulation C: Body temperature irrigation or ice pack application to the pinna	S: Cold water A: Injection in to air canal D: 1 session	T: 9 C: 9	A: 60.22 (15.72) G: 3 (6) D: NR (30-180)	A: NRS B: NR C: NR

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

O'Neill, 2018[65]	T: Randomised trial C: Crossover B: Double	T: Neuromodulation S: tDCS <sup>A</sup> C: Current only applied for 5 seconds	S: 1.4mA A: M1 <sup>B</sup> D: Daily for 5 days	T: 24 C: 9	A: NR G: 7 (2) D: NR	A: NRS B: HADS <sup>7</sup> C: NR
Ojala, 2021[68]	T: Randomised trial C: Crossover B: Double	T: Neuromodulation S: rTMS <sup>C</sup> C: non-conductive plastic cover	S: 5050 pulses at 10Hz, 90% of MT A: M1 and S2 <sup>E</sup> as separate sessions D: 2 weeks per crossover session	T: 17 C: 17	A: 58.80 (7.10) G: 8 (9) D: 67.2 (38.4)	A: NRS B: BDI <sup>12</sup> , PASS-20 <sup>13</sup> , EQ-5D-3L <sup>14</sup> C: DASH <sup>15</sup>
Onouchi, 2014[69]	T: Open-label C: Comparison B: None	T: Pharmacological S: Pregabalin C: Another pain group	S: 300mg to 600mg A: Daily pill D: 52 weeks	T: 100 C: 60	A: 61.70 (8.50) G: 42 (18) D: NR	A: BPI <sup>16</sup> , VAS, SF-MPQ B: NR C: NR
Xiao-nong, 2012[95]	T: Crossover C: Comparison trial B: None	T: Physical S: Acupuncture C: Western Medicine	S: Puncture of acupoints 8-12 mm to 20-40mm in depth, 0.4g to 1.2g of carbamazepine A: NR D: 15 minutes	T: 11 C: 11	A: NR G: 4 (2) D: NR	A: VAS B: NR C: NR
Zhao, 2021[100]	T: Randomised trial C: Sham-control B: Double	T: Neuromodulation S: rTMS <sup>C</sup> C: Identical coil with sound but no stimulation	S: 1500 pulses at 10HZ, 80% of MT A: M1 D: 6 days per week for 3 weeks	T: 38 C: 38	A: 49.55 (11.29) G: 19 (19) D: 6.24 (RI)	A: NRS, SF-MPQ-CN <sup>17</sup> B: HAM-A, HAM-D C: NR

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Boccard, 2012[11]	T: Cross sectional C: None B: None	T: Neuromodulation S: DBS <sup>F</sup> C: None	S: 5 to 50Hz, pulse width 200 to 450ms, amplitude 0.5 to 5V A: PVG <sup>G</sup> , VPL <sup>H</sup> , VPM <sup>I</sup> D: 3 months	T: 85 C: 23	A: 58.8 (9.10) G: 14 (2) D: NR	A: VAS, MPQ <sup>18</sup> B: EQ-5D C: SF-36 <sup>19</sup>
Choi, 2021[16]	T: Retrospective C: None B: None	T: Neuromodulation S: PNB <sup>J</sup> C: None	S: 3 ampoules of 1.8 ml solution each with 36 mg/1.8 ml lidocaine HCl and 0.009 mg/1.8 ml epinephrine A: Ulnar nerve blocks in proximal forearm or femoral, obturator and sciatic nerve blocks in proximal thigh D: 1 day	T: 22 C: 22	A: 56.27 (13.33) G: 8 (14) D: 11.40 (16.66)	A: BPI B: NR C: NR
Gou, 2022[26]	T: Retrospective C: None B: None	T: Neuromodulation S: MCS <sup>K</sup> C: None	S: 30-50 HZ, pulse width 210–300 µs at 3.5 – 7.0 V A: M1 D: 5-7 days	T: 21 C: 21	A: 58.52 (7.27) G: NR D: 34.38 (28.39)	A: VAS, NPSI <sup>20</sup> B: PSQI <sup>21</sup> C: NR
Kim, 2019[43]	T: Cross sectional C: None B: None	T: Pharmacological S: Duloxetine C: None	S: 30mg-60mg once daily A: Daily pill D: 3 weeks	T: 37 C: 37	A: 48.90 (12.10) G: 16 (21) D: 37.2 (49.2)	A: NRS, SF-MPQ B: NR C: NR

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Lefaucheur, 2004[52]	T: Randomised within-subjects trial C: Sham-control B: Single	T: Neuromodulation S: rTMS <sup>C</sup> C: Magstim placebo coil	S: 20 pulses of 5 seconds at 10HZ, 80% MT A: M1 D: NR	T: 60 C: 12	A: RI G: RI D: NR	A: VAS B: NR C: NR
Lin, 2018[56]	T: Cross sectional C: None B: None	T: Neuromodulation S: rTMS <sup>C</sup> C: None	S: 1000 pulses at 10HZ daily, 90% MT A: M1 D: 10 days	T: 7 C: 7	A: 53.57 (7.16) G: 5 (2) D: 44.4 (6-132)	A: VAS B: HAM-A, HAM-D C: Laser Evoked Potentials
Matsumura, 2012[58]	T: Within-subjects C: Placebo control B: NR	T: Neuromodulation S: rTMS <sup>C</sup> C: Coils elevated at an angle of 45° from the skull	S: 500 pulses at 5 Hz, 100% MT A: M1 D: 1 day	T: 20 C: 20	A: 63.60 (8.10) G: 12 (8) D: 38.15 (6 –190)	A: VAS, PGIC B: NR C: NR
Mohamed, 2010[62]	T: Retrospective C: None B: None	T: Neuromodulation S: SCS <sup>L</sup> C: None	S: RI A: Spinal level C4 to C7 for upper limb pain or T9 to T12 for lower limb D: 2-7 days trial, then permanent	T: 30 C: 30	A: 64.80 (7.40) G: 21 (9) D: 44.80 (6 –156)	A: VAS B: NR C: NR
Ohn, 2012[67]	T: Cross sectional C: None B: None	T: Neuromodulation S: rTMS <sup>C</sup> C: None	S: 1000 pulses at 10HZ, 90% MT A: M1 D: 5 times per day for 5 days	T: 22 C: 22	A: 54.90 (9.00) G: 13 (9) D: 21.90 (17.20)	A: VAS B: HAM-D C: NR



16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Owen, 2006[71]	T: Cross sectional C: None B: None	T: Neuromodulation S: DBS <sup>F</sup> C: None	S: NR A: VPL, PVG D: 1 week	T: 15 C: 15	A: 58.60 (37 - 74) G: 12 (3) D: 62.4 (NR)	A: VAS, MPQ B: NR C: NR
Quesada, 2019[74]	T: Randomised trial C: Sham-control B: Double	T: Neuromodulation S: rTMS <sup>C</sup> C: Sham train side of coil	S: 1600 pulses at 20 Hz, 80% MT A: M1 D: 27 minute session	T: 42 C: 19	A: RI G: RI D: RI	A: VAS, NPSI B: EQ-5D C: NR
Shimodozono, 2009[79]	T: Cross sectional C: None B: None	T: Pharmacological S: Fluvoxamine C: None	S: 25mg to 125mg A: Daily pill D: Daily for 2 to 4 weeks	T: 28 C: 28	A: 62.20 (9.70) G: 13 (15) D: NR (1-108)	A: VAS B: SDS <sup>22</sup> C: NR
Tanei, 2019[84]	T: Retrospective C: None B: None	T: Neuromodulation S: SCS <sup>L</sup> C: None	S: 30Hz with pulse width 240 $\mu$ s A: Midline ipsilateral to area of pain D: 12 months	T: 18 C: 18	A: 63.90 (8.80) G: 10 (8) D: 54 (43.20)	A: VAS B: NR C: NR
Zhang, 2018[99]	T: Cross sectional C: None B: None	T: Neuromodulation S: MCS <sup>K</sup> C: None	S: 30-50 HZ, pulse width 210–300 $\mu$ s at 3.5 – 7.0 V A: M1 D: 5-7 days	T: 16 C: 16	A: 59.9 (7.80) G: 8 (8) D: NR	A: VAS, NPSI B: NR C: NR

**A** Transcranial Direct Current Stimulation; **B** Primary Motor Cortex; **C** Repetitive Transcranial Magnetic Stimulation; **D** Motor threshold; **E** Secondary somatosensory cortex; **F** Deep Brain Stimulation; **G** Periventricular grey; **H** Ventral posterolateral nucleus (thalamus); **I** Ventral Posteromedial nucleus; **J** Peripheral Nerve Block; **K** Motor Cortex Stimulation; **L** Spinal Cord Stimulation;

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**1** Visual Analogue Scale; **2** Quantitative Sensory Testing; **3** Brief Pain Inventory (0 to 10); **4** Neuropathic Pain scale; **5** Hamilton Rating Scale – Anxiety; **6** Hamilton Rating Scale – Depression; **7** Hospital Anxiety and Depression Scale; **8** Numeric Rating Scale (0 to 100); **9** Short-form McGill Pain Questionnaire; **10** Pain Disability Index; **11** Patient Global Impression of Change; **12** Beck Depression Inventory; **13** Pain Anxiety Symptoms Scale; **14** European Quality of Life 5 Dimensions 3 Level Version; **15** Disabilities of the Arm, Shoulder, and Hand; **16** Brief Pain Inventory (0 to 10); **17** SF-MPQ Mandarin Chinese version; **18** McGill Pain Questionnaire; **19** Short Form 36-Item Survey Instrument; **20** Neuropathic Pain Symptom Inventory; **21** Pittsburgh Sleep Quality Index; **22** Self-rating Depression Scale; \*Reporting Indiscernible – not possible to extract exact numerical value; \*\*Not Reported

Table 5 Study Risk of bias and Certainty of evidence; Random-Effects meta-analysis in grey, and proportional meta-analysis in white

Study ID	Risk of Bias Tool	Risk of Bias Score	GRADE Score
Bae, 2014	RoB 2: Control Trials	Some Concerns	Moderate
Bainton, 1992	ROB 2: Crossover	Some Concerns	Moderate
Cho, 2013	RoB 2: Control Trials	High	Low
De Oliveira, 2014	RoB 2: Control Trials	High	Moderate
Kim, 2011	RoB 2: Control Trials	Low	High
Mahesh, 2022	RoB 2: Control Trials	Some Concerns	High
McGeoch, 2008	RoB 2: Control Trials	High	Very Low
O'Neill, 2018	ROB 2: Crossover	Low	High
Ojala, 2021	ROB 2: Crossover	Some Concerns	High
Onouchi, 2014	Newcastle-Ottawa	Some Concerns	Low
Xiao-nong, 2012	ROB 2: Crossover	High	Very Low
Zhao, 2021	RoB 2: Control Trials	Low	Moderate
Boccard, 2012	Newcastle-Ottawa	Low	Low
Choi, 2021	Newcastle-Ottawa	Some Concerns	Low
Gou, 2022	Newcastle-Ottawa	Some Concerns	Very Low
Kim, 2019	Newcastle-Ottawa	High	Very Low
Lefaucheur, 2004	RoB 2: Control Trials	High	Moderate
Lin, 2018	Newcastle-Ottawa	High	Very Low
Matsumura, 2012	RoB 2: Control Trials	Some Concerns	High
Mohamed, 2010	Newcastle-Ottawa	Some Concerns	Low
Ohn, 2012	Newcastle-Ottawa	Some Concerns	Very Low
Owen, 2006	Newcastle-Ottawa	Some Concerns	Very Low
Quesada, 2019	ROB 2: Crossover	Low	High
Shimodozono, 2009	Newcastle-Ottawa	Some Concerns	Very Low
Tanei, 2019	Newcastle-Ottawa	Some Concerns	Very Low
Zhang, 2018	Newcastle-Ottawa	Some Concerns	Very Low

## Figure Legends

Figure 1: PRISMA flowchart of literature review

Figure 2: Distribution of CPSP participant stroke locations, y axis is number of participants, and x axis is the stroke location.

Figure 3: Distribution of CPSP participant qualities of pain, y axis is number of participants, and x axis is the pain quality.

Figure 4: Meta-analysis results and forest plot from Neuromodulation studies.

Figure 5: Proportional Meta-analysis results and forest plot from Neuromodulation studies.

Figure 6: Random-Effects Meta-analysis results and forest plot from Pharmacological studies

Figure 7: Proportional Meta-analysis results and forest plot from Pharmacological studies

Figure 8: Random-Effects Meta-analysis results and forest plot from Acupuncture studies

Figure 2: Distribution of CPSP participant stroke locations, y axis is number of participants, and x axis is the stroke location.




Figure 3: Distribution of CPSP participant qualities of pain, y axis is number of participants, and x axis is the pain quality.




Figure 4: Meta-analysis results and forest plot from Neuromodulation studies.




Figure 5: Proportional Meta-analysis results and forest plot from Neuromodulation studies.






Figure 6: Random-Effects Meta-analysis results and forest plot from Pharmacological studies




Figure 7: Proportional Meta-analysis results and forest plot from Pharmacological studies




Figure 8: Random-Effects Meta-analysis results and forest plot from Acupuncture studies





Figure 1: PRISMA flowchart of literature review





## PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
<b>TITLE</b>			
Title	1	Identify the report as a systematic review.	Title Page
<b>ABSTRACT</b>			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Abstract Page
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Manuscript Pages 1-2
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Manuscript page 2
<b>METHODS</b>			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Manuscript page 5
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Table 1
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Manuscript page 5
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Manuscript page 5
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Manuscript page 5-7
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Manuscript page 9
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Manuscript page 9
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Manuscript page 7
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Manuscript page 9
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Manuscript page 9
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Manuscript page 9
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Manuscript page 9
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Manuscript page 9
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	Manuscript page 9
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Manuscript page 9
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	Manuscript page 9
Certainty	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	Manuscript page 7-



# PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
assessment			9
<b>RESULTS</b>			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Page 9, Figure 1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Page 9, Figure 1
Study characteristics	17	Cite each included study and present its characteristics.	Table 4, Supplementary table 1
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Table 5
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Pages 17-22, Figure 2-8
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Pages 17-22, Figure 2-8
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Pages 17-22, Figure 2-8
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Pages 17-22, Figure 2-8
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Pages 17-22, Figure 2-8
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Table 5
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Table 5
<b>DISCUSSION</b>			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Page 23-26
	23b	Discuss any limitations of the evidence included in the review.	Page 25
	23c	Discuss any limitations of the review processes used.	Page 25
	23d	Discuss implications of the results for practice, policy, and future research.	Page 26
<b>OTHER INFORMATION</b>			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	CRD42022371835
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	CRD42022371835
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	Amended to include additional databases
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Funded by Medical Research Council as part of PhD. Stated in



## PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
			Acknowledgements
Competing interests	26	Declare any competing interests of review authors.	Stated in Acknowledgements
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	none

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: <http://www.prisma-statement.org/>